Lasmiditan for single migraine attack in Japanese patients with cardiovascular risk factors: subgroup analysis of a phase 2 randomized placebo-controlled trial

Hashimoto, Y; Komori, M; Tanji, Y; Ozeki, A; Hirata, K

Komori, M (通讯作者)，Eli Lilly Japan KK, Japan Drug Dev & Med Affairs, Chuo Ku, 5-1-28 Isogamidori, Kobe, Hyogo 6510086, Japan.

EXPERT OPINION ON DRUG SAFETY, 2022; 21 (12): 1495

Abstract

Background Some migraine treatments are contraindicated for patients with cardiovascular disease (CVD) or risk factors (CVRFs). We report safety and e......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索